M&A · Healthcare · Pharmaceutical Preparations
Viatris Inc to acquire Pacira BioSciences, Inc.
Announced Oct 8, 2026 · Pending Oct 30, 2026
Deal value$1.65BEV $1.81B
Premium45.0%To unaffected price
EV / Adj. EBITDA9.5x2.4x EV / Revenue
ConsiderationAll cash$36.50 per share
Transaction
- Acquirer
- Viatris Inc (VTRS)
- Target
- Pacira BioSciences, Inc. (PCRX)
- Buyer type
- Strategic
- Offer price per share
- $36.50
- Enterprise value
- $1.81B
- Status
- Pending Oct 30, 2026
Deal protections
- Break fee (target pays)
- $62.0M · 3.8%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Morgan Stanley
- To the target
- Goldman Sachs, Centerview
Sector context · Healthcare
- Comparable deals
- 108 in the prior 24 months
- Premium
- 45.0% vs. 44.5% sector median
- EV / Adj. EBITDA
- 9.5x vs. 10.9x sector median
- Break fee
- 3.8% vs. 3.5% sector median
Timeline
- AnnouncedOct 8, 2026
- Tender offerOct 30, 2026
- ClosedPending